West Pharmaceutical Services Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 23 July 2026: press release. Guidance figures: 4 raised, 1 lowered, 4 new, 1 kept. The quarter’s numbers.

Read the filing

Key takeaways

• Net sales up 13.8%, organic 12.7%: Net sales were $872.3 million against $766.5 million a year earlier. Currency added 1.1 points to reported growth; organic growth was 12.7%. Source
• Full-year sales and EPS guidance raised: Full-year net sales guidance raised to $3.345 billion to $3.380 billion, and adjusted-diluted EPS guidance raised to $8.85 to $9.05. Capital guidance unchanged. Source
• HVP Components up 19.4%: HVP Components net sales were $424.1 million, up 18.4% organic, and 49% of total company net sales in the quarter. Source
• Gross margin rose to 37.7%: Gross profit was $329.2 million, a 37.7% margin against 35.7% a year earlier. Cost of goods sold was 62% of net sales against 64%. Source
• Operating cash flow and free cash flow: The second-quarter summary lists operating cash flow of $213.9 million and free cash flow of $128.0 million; these match the six months ended June 30 cash flow statement. Source
• Buybacks of $454.3 million in first half: Repurchases totaled 1.8 million shares for $454.3 million in the six months, against $134.0 million a year earlier. Treasury stock reached $1,512.3 million at June 30. Source

“Net sales increased 12.7% organically, driven by our High Value Product Components business which benefited from continued strength in Biologics, a favorable mix shift from HVP upgrades including Annex 1, and ongoing growth in GLP-1 elastomers.”

Eric M. Green, President, Chief Executive Officer and Chair of the Board

Guidance

What changed from last quarter

• Guidance raised: Full-year net sales guidance range raised to $3.345 billion to $3.380 billion from $3.295 billion to $3.350 billion. Source
• Guidance raised: Full-year adjusted-diluted EPS guidance raised to $8.85 to $9.05 from $8.40 to $8.75. Source
• Guidance raised: Full-year reported diluted EPS guidance raised to $9.01 to $9.26 from $8.15 to $8.50. Source
• Guidance lowered: Full-year currency benefit to net sales estimated at about 1 point, down from about 2 points in the first-quarter release. Source
• New guidance: Third-quarter 2026 net sales guidance range of $820 million to $835 million introduced. Source
• New guidance: Third-quarter 2026 adjusted-diluted EPS guidance range of $2.14 to $2.24 introduced. Source

Results and growth drivers

• Net sales up 13.8%, organic 12.7%: Net sales were $872.3 million against $766.5 million a year earlier. Currency added 1.1 points to reported growth; organic growth was 12.7%. Source
• Diluted and adjusted EPS both rose: Diluted EPS was $2.15 against $1.82, up 18.1%. Adjusted-diluted EPS was $2.37 against $1.84, up 28.8%, after $0.22 of unallocated items. Source
• Operating profit and net income higher: Operating profit was $179.1 million against $153.7 million. Net income was $154.0 million against $131.8 million a year earlier. Source
• Full-year sales and EPS guidance raised: Full-year net sales guidance raised to $3.345 billion to $3.380 billion, and adjusted-diluted EPS guidance raised to $8.85 to $9.05. Capital guidance unchanged. Source

Segments and regions

• Proprietary Products up 16.6%: Proprietary Products net sales were $722.6 million against $619.8 million, organic growth 15.5%. Segment operating profit rose to $211.9 million from $161.7 million. Source
• West Vantage nearly flat organically: West Vantage net sales were $149.7 million, up 2.0% reported and 0.8% organic. Segment operating profit fell to $12.9 million from $17.8 million. Source
• Asia Pacific organic growth 27.0%: Asia Pacific net sales rose 24.9% to $83.8 million, 27.0% organic. Europe, Middle East and Africa rose 14.3% to $399.8 million; Americas rose 11.2% to $388.7 million. Source

“As a result of our team's strong execution in the second quarter and improved outlook, we are increasing our full-year 2026 guidance.”

Eric M. Green, President, Chief Executive Officer and Chair of the Board

Products and customers

• HVP Components up 19.4%: HVP Components net sales were $424.1 million, up 18.4% organic, and 49% of total company net sales in the quarter. Source
• HVP Delivery Devices up 29.6%: HVP Delivery Devices net sales were $131.2 million, up 29.2% organic, and 15% of total company net sales. Source
• Standard Products up 2.4%: Standard Products net sales were $167.3 million, up 0.7% organic, and 19% of total company net sales. Source
• Biologics sales up 30.3%: Biologics net sales were $374.8 million, up 29.2% organic. Pharma rose 3.3% to $205.0 million; Generics rose 6.9% to $142.8 million. Source

Margins and costs

• Gross margin rose to 37.7%: Gross profit was $329.2 million, a 37.7% margin against 35.7% a year earlier. Cost of goods sold was 62% of net sales against 64%. Source
• General corporate costs rose: General corporate costs were $34.8 million against $18.4 million. SG&A was $117.6 million against $95.9 million, 14% of net sales. Source
• Unallocated items rose sharply: Unallocated items were $18.3 million against $1.6 million. Nonrecurring professional fees for legal matters and the cybersecurity incident sit in the other items line of $6.9 million. Source
• Other expense rose to $12.8M: Other expense was $12.8 million against $5.2 million. It includes $1.3 million of SmartDose sale employee benefit costs, a $3.5 million impairment and $1.0 million of restructuring depreciation. Source

Currency and organic growth basis

• Currency added 1.1 points in quarter: Currency was a 1.1 point benefit to reported growth in the quarter. Third-quarter guidance carries an estimated currency headwind of about 1 point at current exchange rates. Source
• SmartDose excluded from organic base: SmartDose 3.5mL net sales of $55 million in second-half 2025 are excluded from full-year organic guidance; $30 million of third-quarter 2025 sales is excluded from the third-quarter base. Source

Cash, capital and shareholder returns

• Operating cash flow and free cash flow: The second-quarter summary lists operating cash flow of $213.9 million and free cash flow of $128.0 million; these match the six months ended June 30 cash flow statement. Source
• Working capital absorbed $188.9M: Changes in assets and liabilities used $188.9 million in the six months, against $4.0 million a year earlier. Accounts receivable rose to $712.0 million from $574.4 million at year-end. Source
• Buybacks of $454.3 million in first half: Repurchases totaled 1.8 million shares for $454.3 million in the six months, against $134.0 million a year earlier. Treasury stock reached $1,512.3 million at June 30. Source
• Dividend payments and cash balance: Dividend payments were $31.5 million in the six months. Cash and equivalents were $435.8 million at June 30, against $791.3 million at December 31, 2025. Source
• Capital spending guidance unchanged: Full-year capital spending guidance is $250 million to $275 million, unchanged. First-half capital expenditures were $85.9 million against $146.5 million. Source

Strategy, portfolio and investments

• SmartDose 3.5mL sale to AbbVie: The company has agreed to sell its SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie. Second-quarter M&A charges, including the sale, were $6.4 million. Source
• Daikyo ownership amortization: Amortization tied to the increased ownership interest in Daikyo was $0.4 million in the quarter, against $0.5 million a year earlier. Source
• Cost-method investment impaired: Cost-method investment impairment charges of $3.5 million were recorded within other expense in the quarter. Source
• Restructuring charges modest this quarter: Restructuring charges were $1.5 million in the second quarter, against $1.6 million a year earlier, under the January 2025 plan and the 2024 legal structure plan. Source

EPS reconciliation and share count

• Reported EPS guidance above adjusted: The SmartDose M&A line in the 2026 EPS bridge is a negative $0.54 to $0.59 per share, so reported diluted EPS guidance sits above adjusted guidance. Source
• Second-quarter EPS bridge to $2.37: Diluted EPS of $2.15 adjusts to $2.37 after $0.22 of items: M&A $0.07, other $0.08, cost-method investment $0.05 and restructuring $0.02. Source
• Diluted share count fell: Average diluted shares were 71.3 million in the quarter against 72.5 million a year earlier. Shares outstanding were 70.4 million at June 30. Source

Coming up, as management said on 23 July 2026

• Third-quarter dividend declared: The board declared a third-quarter 2026 dividend of $0.22 per share on July 21, 2026. The release gives no payment date. Source

Figures management reported

Risks management discussed

• Operational: Nonrecurring professional fees tied to the May 2026 cybersecurity incident and certain legal matters were recorded in SG&A and excluded from adjusted results. Source
• External: Third-quarter net sales guidance includes an estimated currency headwind of about 1 point at current exchange rates. Source

Earlier plans management reported on

• Ahead: Management said second-quarter net sales and adjusted EPS exceeded its expectations. Reported net sales were $872.3 million against the $830 million to $850 million guidance set in April. Source
• Not stated: The April release said first-quarter full-year guidance continued to assume a mid-year close for the SmartDose 3.5mL sale to AbbVie. The July release does not state timing.

Other quarters

• Q1 FY2026 earnings call
• Q4 FY2025 earnings call
• Q3 FY2025 earnings call
• Q2 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.